Psilocybin for PTSD in Veterans Trial

Bottom line: A Phase 2 trial completed in 2026 may suggest psilocybin-assisted therapy was associated with potential benefits for PTSD in U.S. veterans, but results are not yet available.

A trial completed in 2026 looked at whether psilocybin, a compound found in certain mushrooms, could help veterans with PTSD. The study was conducted in a controlled therapeutic setting and is part of growing interest in using psychedelics for mental health.

What’s being tested

This trial examined whether psilocybin-assisted therapy is safe and effective for treating PTSD in U.S. military veterans. PTSD is a mental health disorder that often develops after exposure to traumatic events, and veterans are more likely than the general population to experience it. The intervention involved administering psilocybin in a controlled therapeutic setting. The study aimed to see if this approach could reduce PTSD symptoms and improve overall well-being.

The design at a glance

The trial was a Phase 2 study completed in 2026. Phase 2 trials usually look at how well a treatment works while continuing to assess safety in a group of participants. The sponsor was Ohio State University, which has experience in clinical research and mental health. The trial included a structured therapeutic environment, likely with guided sessions and follow-up assessments to track outcomes. This phase was important for gathering early data on whether psilocybin might be a viable treatment, but it did not prove its effectiveness.

Why it matters

PTSD is linked to serious psychological distress, lower quality of life, and higher rates of depression and substance use. A safe and effective treatment could help many veterans and ease the long-term strain on healthcare systems. Interest in psilocybin for PTSD is part of a larger effort to explore psychedelics for mental health, driven by increasing evidence of their possible benefits.

What this does NOT mean yet

This trial is complete, but results have not been released yet. That means no conclusions about psilocybin’s effectiveness for PTSD can be made based on this study. A completed trial does not mean the treatment is approved or recommended. Many trials do not find positive results, and the findings need to be interpreted carefully. The completion of the study marks the end of the research phase, but the data must be analyzed and published before its impact can be known. Until results are available, this remains a question being asked, not an answer found.

How to follow it

For the most recent information about the trial’s findings, visit the ClinicalTrials.gov record at https://clinicaltrials.gov/study/NCT05554094. This is where the trial’s results, if published, will be posted. The site also provides details on the study’s design, who participated, and what outcomes were measured, giving a clear view of the research process.

Sources

https://clinicaltrials.gov/study/NCT05554094 | NCT05554094

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.